ACC Action Center

Episodes 17-25 of 25

• 

  RestartResume

  PCSK9i Reduces Plaque Burden in Coronary Arteries 

  RestartResume

  PCSK9i Reduces Plaque Burden in Coronary Arteries 

  ACC Action Center

  PCSK9i Reduces Plaque Burden in Coronary Arteries 

• 

  RestartResume

  Cardiac Myosin Inhibitor Sustainably Reduces LVOT Gradient in HCM

  RestartResume

  Cardiac Myosin Inhibitor Sustainably Reduces LVOT Gradient in HCM

  ACC Action Center

  Cardiac Myosin Inhibitor Sustainably Reduces LVOT Gradient in HCM

• 

  RestartResume

  Treatment of Chronic Hypertension Reduces Adverse Pregnancy Outcomes

  RestartResume

  Treatment of Chronic Hypertension Reduces Adverse Pregnancy Outcomes

  ACC Action Center

  Treatment of Chronic Hypertension Reduces Adverse Pregnancy Outcomes

• 

  RestartResume

  Reduction of Bleeding with Tranexamic Acid After Noncardiac Surgery

  RestartResume

  Reduction of Bleeding with Tranexamic Acid After Noncardiac Surgery

  ACC Action Center

  Reduction of Bleeding with Tranexamic Acid After Noncardiac Surgery

• 

  RestartResume

  Beginning of an Era: Treatment of Elevated Lp(a)

  RestartResume

  Beginning of an Era: Treatment of Elevated Lp(a)

  ACC Action Center

  Beginning of an Era: Treatment of Elevated Lp(a)

• 

  RestartResume

  Updates in the New AHA/ACC/HFSA Heart Failure Guideline

  RestartResume

  Updates in the New AHA/ACC/HFSA Heart Failure Guideline

  ACC Action Center

  Updates in the New AHA/ACC/HFSA Heart Failure Guideline

• 

  RestartResume

  A First Clinical Trial Testing the Use of an H2S Donor After Heart Attack 

  RestartResume

  A First Clinical Trial Testing the Use of an H2S Donor After Heart Attack 

  ACC Action Center

  A First Clinical Trial Testing the Use of an H2S Donor After Heart Attack 

• 

  RestartResume

  Study with ASO Targeting ANGPTL3 mRNA Highlights Importance of Rigorous Evaluation of New Therapies 

  RestartResume

  Study with ASO Targeting ANGPTL3 mRNA Highlights Importance of Rigorous Evaluation of New Therapies 

  ACC Action Center

  Study with ASO Targeting ANGPTL3 mRNA Highlights Importance of Rigorous Evaluation of New Therapies 

• 

  RestartResume

  Reductions in LVOT Gradients, NYHA Class, & NT-proBNP with Cardiac Myosin Inhibitor in HCM

  RestartResume

  Reductions in LVOT Gradients, NYHA Class, & NT-proBNP with Cardiac Myosin Inhibitor in HCM

  ACC Action Center

  Reductions in LVOT Gradients, NYHA Class, & NT-proBNP with Cardiac Myosin Inhibitor in HCM

• Previous
• 1
• 2
• Next